Bill Feehery 의 보수는 Certara 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$61m
Dec 31 2023	US$8m	US$796k	-US$55m
Sep 30 2023	n/a	n/a	-US$34m
Jun 30 2023	n/a	n/a	US$19m
Mar 31 2023	n/a	n/a	US$14m
Dec 31 2022	US$6m	US$796k	US$15m
Sep 30 2022	n/a	n/a	-US$4m
Jun 30 2022	n/a	n/a	-US$10m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$6m	US$773k	-US$13m
Sep 30 2021	n/a	n/a	-US$58m
Jun 30 2021	n/a	n/a	-US$55m
Mar 31 2021	n/a	n/a	-US$49m
Dec 31 2020	US$4m	US$773k	-US$49m
Sep 30 2020	n/a	n/a	-US$965k
Jun 30 2020	n/a	n/a	US$601k
Mar 31 2020	n/a	n/a	-US$5m
Dec 31 2019	US$4m	US$438k	-US$9m

보상 대 시장: Bill 의 총 보상 ($USD 7.81M )은 US 시장( $USD 5.67M ).

보상과 수익: 회사가 수익성이 없는 동안 Bill 의 보상이 증가했습니다.

CEO

Bill Feehery (53 yo)

5yrs

테뉴어

US$7,810,028

보상

Dr. William F. Feehery, also known as Bill, Ph.D. serves as Chief Executive Officer of the Certara, Inc. since June 2019 and Director since 2012. He had been the President of Industrial Biosciences Busines...

리더십 팀

이름	위치	테뉴어	보상	소유권
William Feehery	CEO & Director	5yrs	US$7.81m	1.38% $ 30.7m
Leif Pedersen	President & Chief Commercial Officer	less than a year	US$2.14m	0.089% $ 2.0m
John Gallagher	SVP, Principal Accounting Officer & Chief Financial Officer	1.2yrs	US$4.24m	0.011% $ 252.4k
Robert Aspbury	President of Certara Scientific Software	4.4yrs	US$2.09m	0.18% $ 3.9m
Patrick Smith	President of Certara Drug Development Solutions	2.6yrs	US$2.42m	0.031% $ 693.7k
Max Kanevsky	Chief Technology Officer	1.4yrs	데이터 없음	데이터 없음
Daniel Corcoran	Chief Counsel	less than a year	데이터 없음	데이터 없음
Ron DiSantis	Senior Vice President of Corporate Development	no data	데이터 없음	데이터 없음
Sheila Rocchio	Chief Marketing Officer	less than a year	데이터 없음	데이터 없음
Rona Anhalt	Chief Human Resources Officer	less than a year	데이터 없음	데이터 없음
Frederic Bois	Senior Scientific Advisor	5.2yrs	데이터 없음	데이터 없음
David Mitchell	Senior Vice President of Strategic Engagement	2.8yrs	데이터 없음	데이터 없음

1.4yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: CERT 의 관리팀은 경험 (평균 재직 기간 1.4 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
William Feehery	CEO & Director	5yrs	US$7.81m	1.38% $ 30.7m
Frederic Bois	Senior Scientific Advisor	5.2yrs	데이터 없음	데이터 없음
James Cashman	Independent Chairman of the Board	6.1yrs	US$319.51k	0.28% $ 6.3m
Matthew Walsh	Independent Director	3.8yrs	US$252.01k	0.12% $ 2.6m
Eran Broshy	Independent Director	1.9yrs	US$252.01k	0.014% $ 318.8k
Malcolm Rowland	Chair of Simcyp Scientific Advisory Board	no data	데이터 없음	데이터 없음
Yuichi Sugiyama	Member of Simcyp Scientific Advisory Board	no data	데이터 없음	데이터 없음
Nancy Killefer	Independent Director	2.8yrs	US$252.01k	0.015% $ 334.6k
Donald Mager	Member of Simcyp Scientific Advisory Board	no data	데이터 없음	데이터 없음
Geoff Tucker	Member of Simcyp Scientific Advisory Board	no data	데이터 없음	데이터 없음
Lawrence Lesko	Member of Simcyp Scientific Advisory Board	8.8yrs	데이터 없음	데이터 없음
J Houston	Member of Simcyp Scientific Advisory Board	no data	데이터 없음	데이터 없음

5.0yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: CERT 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.

Certara 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Certara, Inc Appoints Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel

Certara, Inc., Annual General Meeting, May 21, 2024

Insider notifies of intention to sell stock

President & Chief Commercial Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

CEO & Director exercised options and sold US$370k worth of stock

Recent updates

Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software

Certara (NASDAQ:CERT) Is Looking To Continue Growing Its Returns On Capital

Certara, Inc Appoints Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel

Certara, Inc. Reiterates Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Certara, Inc. Launches Cloud Platform to Further Unify Its End-To-End Scientific Software Platform

Certara, Inc., Annual General Meeting, May 21, 2024

When Should You Buy Certara, Inc. (NASDAQ:CERT)?

Certara, Inc. to Report Q1, 2024 Results on May 07, 2024

Insider notifies of intention to sell stock

Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk

Consensus EPS estimates increase by 100%

Full year 2023 earnings: EPS misses analyst expectations

Certara, Inc. Provides Earnings Guidance for the Year 2024

Returns Are Gaining Momentum At Certara (NASDAQ:CERT)

Certara, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth

Price target increased by 8.3% to US$18.57

Certara, Inc. (NasdaqGS : CERT) acquired Applied BioMath, LLC.

Calculating The Fair Value Of Certara, Inc. (NASDAQ:CERT)

Certara, Inc. Announces the Introduction of Simcyp Biopharmaceutics Software

Certara, Inc. Provides Revenue Guidance for the Year 2023

Price target decreased by 7.5% to US$17.71

Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)

Price target decreased by 9.7% to US$18.57

Certara, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?

President & Chief Commercial Officer notifies of intention to sell stock

An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued

Consensus EPS estimates fall by 39%

Price target decreased by 9.1% to US$21.19

Certara, Inc. Updates Earnings Guidance for the Year 2023

Certara (NASDAQ:CERT) Shareholders Will Want The ROCE Trajectory To Continue

Certara, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Insider notifies of intention to sell stock

Consensus EPS estimates fall by 20%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Certara, Inc. Provides Revenue Guidance for the Year 2023

CEO & Director exercised options and sold US$370k worth of stock

Consensus EPS estimates increase by 11%

Consensus EPS estimates increase by 15%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Senior VP notifies of intention to sell stock

Certara, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Certara, Inc. (NasdaqGS:CERT) acquired VYASA Analytics LLC.

Forecast breakeven date pushed back to 2023

Certara, Inc. Announces the Resignation of Mason Slaine as Director of the Company

Arsenal Capital Partners completed the acquisition of an additional 18.8% stake in Certara, Inc. (NasdaqGS:CERT) from EQT Avatar Parent L.P.

Certara, Inc. Appoints David Spaight to the Board of Directors

President of Software notifies of intention to sell stock

Now 22% undervalued after recent price drop

Price target decreased to US$20.56

Price target decreased to US$20.56

Third quarter 2022 earnings released: EPS: US$0.025 (vs US$0.012 loss in 3Q 2021)

Certara, Inc. Reaffirms Earnings Guidance for the Full Year 2022

Japan's Pharmaceuticals and Medical Devices Agency Renews Licenses of Certara's Software for Evaluating Regulatory Submissions

Certara, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Certara: A Story To Watch

Insider recently sold US$3.2m worth of stock

Now 22% undervalued after recent price drop

Certara, Inc. Announces Resignation of Justin Edge as President of Regulatory and Access, Effective September 1, 2022

Certara to raise capital in secondary stock offering

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Certara, Inc. Revises Its Full Year Earnings Guidance of 2022

Certara, Inc. Introduces Update of Pinnacle 21(Tm) Enterprise and New Pinnacle 21(Tm) Data Exchange Module

Certara, Inc. Appoints Rosemary A. Crane, as a Class III Director, Effective July 21, 2022

Certara, Inc. Appoints Eran Broshy as New Independent Board Member, Effective July 11, 2022

Certara, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development